Pharmaceutical Companies Deploy AI to Accelerate Clinical Trials and Cut Costs

Pharmaceutical companies are increasingly deploying artificial intelligence to streamline the administrative and operational hurdles of drug development. At the recent JP Morgan Healthcare Conference, seven large drugmakers and six smaller biotech firms reported utilizing AI tools to manage clinical trial recruitment, regulatory documentation, and site selection. This shift addresses the significant financial and temporal burdens of the industry, where it typically takes a decade and $2 billion to bring a new drug to market.